key: cord-0718658-34mzvas1 authors: Vaselli, Natasha Marcella; Hungerford, Daniel; Shenton, Ben; Khashkhusha, Arwa; Cunliffe, Nigel A.; French, Neil title: The seroprevalence of SARS-CoV-2 during the first wave in Europe 2020: A systematic review date: 2021-11-02 journal: PLoS One DOI: 10.1371/journal.pone.0250541 sha: aacb7748faaac2046c9d32ce445b43f0e8c0df15 doc_id: 718658 cord_uid: 34mzvas1 BACKGROUND: A year following the onset of the COVID-19 pandemic, new infections and deaths continue to increase in Europe. Serological studies, through providing evidence of past infection, can aid understanding of the population dynamics of SARS-CoV-2 infection. OBJECTIVES: This systematic review of SARS-CoV-2 seroprevalence studies in Europe was undertaken to inform public health strategies including vaccination, that aim to accelerate population immunity. METHODS: We searched the databases Web of Science, MEDLINE, EMBASE, SCOPUS, Cochrane Database of Systematic Reviews and grey literature sources for studies reporting seroprevalence of SARS-CoV-2 antibodies in Europe published between 01/12/2019–30/09/20. We provide a narrative synthesis of included studies. Studies were categorized into subgroups including healthcare workers (HCWs), community, outbreaks, pregnancy and children/school. Due to heterogeneity in other subgroups, we only performed a random effects meta-analysis of the seroprevalence amongst HCWs stratified by their country. RESULTS: 115 studies were included spanning 17 European countries, that estimated the seroprevalence of SARS-CoV-2 from samples obtained between November 2019 –August 2020. A total of 54/115 studies included HCWs with a reported seroprevalence among HCWs ranging from 0.7% to 45.3%, which did not differ significantly by country. In community studies significant heterogeneity was reported in the seroprevalence between different age groups and the majority of studies reported there was no significant difference by gender. CONCLUSION: This review demonstrates a wide heterogeneity in reported seroprevalence of SARS-CoV-2 antibodies between populations. Continued evaluation of seroprevalence is required to understand the impact of public health measures and inform interventions including vaccination programmes. Introduction On 11 th March 2020 the World Health Organization (WHO) declared the spread of the novel SARS-CoV-2 virus as a pandemic [1] . SARS-CoV-2 is thought to spread mainly by respiratory droplets, airborne transmission and some evidence also suggests spread via fomites [2] [3] [4] . SARS-CoV-2 causes varying degrees of illness from mild symptoms including fatigue and myalgia to acute respiratory failure and death [5] . As the pandemic unfolded evidence emerged that a large number of individuals are asymptomatic with SARS-CoV-2 infection [6, 7] . It has been suggested that asymptomatic transmission of SARS-CoV-2 could account for at least a third and up to 59% of transmission across the world [4] . In order to control the spread of SARS-CoV-2 it is important to understand the extent to which different populations have already been exposed to the virus, especially as a large number of infections are asymptomatic and therefore may not have been tested for SARS-CoV-2 at the time of infection. Many countries, organizational bodies and facilities have turned to mass testing to estimate the spread of infection and inform public health measures [8, 9] . One such testing strategy is by nasal and throat swabbing to detect viral RNA which has been piloted in England [10] . A further method is mass testing of the population for antibodies against SARS--CoV-2 [11] . Several tests for immunoglobulin G (IgG), immunoglobulin A(IgA) and immunoglobulin M(IgM) antibodies against SARS-CoV-2 have recently been developed. These broadly include enzyme linked immunosorbent assays, chemiluminescence immunoassays (CLIA) and point of care lateral flow assays [12] . Seroprevalence studies have been used in the past to help with outbreak responses. During a recent Ebola outbreak, seroprevalence studies were performed to gain further information on the immune response and immune protection [13] . Seroprevalence studies have also been used for infections such as rubella, mumps and measles to map resurgence and to gain further information on how public health strategies can target high risk populations [14] . Moreover, seroprevalence studies provide valuable information for vaccination strategies as they help to quantify how much of a population has been exposed to the virus helping to achieve herd immunity and helping to identify populations who may be at greater risk of infection. By estimating the seroprevalence in different populations we can use the results to understand transmission dynamics, herd immunity and the immune response over time. These studies can help to guide the public health response to ultimately help prevent the spread of SARS-CoV-2. Here we present the results of a systematic review on the seroprevalence of SARS-CoV-2 in Europe. This systematic review and meta-analysis adheres to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [15] . The protocol was registered on the Titles and abstracts of retrieved studies were de-duplicated and screened independently by two reviewers to identify if they met the inclusion criteria. Screened references then underwent full text review by two reviewers independently. Any disagreement between them over the eligibility of studies was resolved through discussion with a third reviewer. A standardised data extraction form was used. Data was extracted on the characteristics of the study (country, date, setting, selection method, funder), antibody assay employed, specificity and sensitivity of the assay, sample characteristics (age, gender, ethnicity, co-morbidities) and prevalence. Data extraction was carried out autonomously by the reviewers and consensus was sought between the team. Data was recorded on the type of funding the studies received; this included government funding, research grants with some studies receiving no external funding. We assessed the risk of bias using an adapted version of the Hoy et al modified Risk of Bias Tool, as used by Nguyen et al [17, 18] . This is a tool designed to assess the risk of bias in population-based prevalence studies. It uses a scoring system to assess the external and internal validity of the study. Studies that score 0-3 points are classified as low risk, 4-6 medium risk and 7-9 high risk. Two reviewers independently applied the criteria. Disagreements were resolved through discussion. After reviewing the relevant literature, we did not perform traditional asymmetry tests and funnel plots for assessing publication bias, as the meta-analysis we conducted was a summary of proportions and not a comparison of treatments/interventions [19, 20] . We provide a narrative synthesis of the findings of all included studies, study population characteristics, antibody assays used and seroprevalence estimates for each study. A narrative synthesis aims to summarise the findings of multiple studies in the form of words and text [21] . Studies were categorized into subgroups including those that examined health care workers (HCWs), community studies, outbreaks, seroprevalence in children/schools and seroprevalence studies performed in pregnant women. We included studies in the subgroup outbreak if they investigated the seroprevalence following a sudden increase in SARS-CoV-2 cases related to time and place in a particular population [22] . We used Metaprop in STATA version 14, statistical software (Stata Corp. College Station, TX, USA), package to perform a random-effects meta-analysis of seroprevalence amongst health care workers (HCWs) stratified by country. The random effect model used the DerSimonian and Laird method with study heterogeneity estimated from the inverse-variance fixed-effect model. The pooled effect estimate was calculated after Freeman-Tukey Double Arcsine Transformation and Wilson score 95% confidence intervals were calculated for individual studies. We also performed a random-effects metaanalysis of seroprevalence amongst health care workers (HCWs) stratified by their risk of exposure to SARS-CoV-2 infected patients. HCWs were categorised as high risk if they worked with patients with known SARS-CoV-2 infection, medium risk if they had patient contact but without known SARS-CoV-2 infection and low risk if they had no patient contact (e.g., laboratory staff and administrative staff). If studies included participants from a mixture of risk groups they were categorised as medium risk. Heterogeneity was measured using the I 2 statistic which describes the percentage of total variation due to inter-study heterogeneity. Tests of heterogeneity were undertaken within the sub-groups and for the overall meta-analysis. Sensitivity analysis was done by removing those studies with a moderate risk of bias score. This had no effect of the I 2 value, so these studies were included in the final meta-analysis. The literature search yielded 2126 articles. After removing duplicates and excluding studies based on their abstract or through full text examination 115 studies were identified as eligible (Fig 1) . The 115 articles spanned 17 countries in Europe and estimated the seroprevalence of SARS-CoV-2 from serum samples dated from November 2019 -August 2020. The 115 articles reviewed the seroprevalence in approximately 516,361 samples; among included studies 59.92% of subjects were females and the overall age range of participants was 0-90+ years (Table 2) . 132, 134, 136] . This was often due to lack of information about the sampling frame, selection process and non-response bias. No studies scored high risk (Table 3) . Health care workers. 54 studies included seroprevalence data among HCWs. These studies included data from 13 countries in Europe and were conducted between February 2020 and August 2020. The lowest seroprevalence was seen in a teaching hospital in Rome, Italy during the months of March-April 2020, reporting a seroprevalence of 0.7% based on IgG antibodies and 0% based on IgM [77] . The highest seroprevalence (45.3%) was reported in March-April 2020 in a University Hospital in London [119] . Fig 2A shows the seroprevalence of HCWs by country Armann et al 2020 [64] 25th May -30th June Students grade 8-11 and their teachers in 13 secondary schools in eastern Saxony Epstude et al 2020 [65] 15th June -30th June HCWs and housekeeping staff in an oncology unit 3.10% Hoffmann et al 2020 [66] 20th July HCWs in a standard care hospital in Oberspreewald-Lausitz Bogogiannidou et al 2020 [67] March and April Psichogiou et al 2020 [68] 30th April -15th May HCWs across two hospitals in Greece 1.00% Tsitsilonis et al 2020 [69] June-July 2020 Student and staff at National and Kapodistrian University of Athens 1.00% Gudbjartsson et al 2020 [70] January-July Two groups of qPCR-positive Icelanders and six groups of Icelanders who had not been qPCRtested or who had been tested and had received a negative result Plebani et al 2020 [71] 22nd February -29th May HCWs in several Structures of the National Healthcare Service of the Veneto Region 4.6% (4.1-5.0%) Valenti et al 2020 [72] 24th February -8th April Blood donors in Milan 5.07% Pancrazzi et al 2020 [73] 17th -21st March Patients in the Emergency Room and from subjects undergoing health surveillance by territorial and hospital prevention departments in Tuscany 13.00% Vena et al 2020 [74] March and April Residents living in Liguria and Lombardi regions 11.00% Norsa et al 2020 [75] March-July Patients with IBD on biologic treatment 21.10% Percivalle et al 2020 [76] 18th March -6th April Registered blood donors in Lodi Italy 23.00% Lahner et al 2020 [77] 18th March-27th April HCWs in a teaching hospital in Rome 0.70% Fusco et al 2020 [78] 23rd March -2nd April HCWs working in a specialist infectious disease setting, the 'D. Cotugno' hospital in Naples, Italy. Sotgiu et al 2020 [79] 2nd -16th April HCWs at San Paulo University General Hospital 7.4% based on IgG Amendola et al 2020 [80] 15th April HCWs in Buzzi Hospital 5.13% Carozzi et al 2020 [81] 20th April HCWs across 6 health facilities in Tuscany 2.4% only including positive results and not borderline results Comar et al 2020 [82] Published in medRxiv in April All employees of the Mother and Child Research Hospital Burlo Garofolo 7.2% just including positive and not borderline results. Cosma et al 2020 [83] 16th April -4th June Pregnant women attending for first trimester screening (11-13 weeks of gestation) at Sant'Anna Hospital, Turin, Piedmont Sandri et al 2020 [84] 28th April -16th May Employees of 7 different hospitals, located across the Lombardy region 11.21% Fiore et al 2020 [85] 1st May -31st May Blood donors in Apulia region, South Eastern Italy 0.99% Pagani et al 2020 [86] 18th Garcia-Basteiro et al 2020 [94] 28th March -9th April HCWs at Hospital Clínic of Barcelona 9.3% (7.1-12%) Valdivia et al 2020 [95] 13th -30th April HCWs at Hospital Clínico Universitario of Valencia Galán et al 2020 [96] 14th -27th April All HCWs Hospital Universitario Fundación Alcorcón Crovetto et al 2020 [97] 14th Martín et al 2020 [100] 20th April General practitioners (GP) and primary care nurses in the Healthcare Area of León, who worked in health centres or nursing homes. Montenegro et al 2020 [101] 21 April to 24 April 2020 (Study population A) and from 29 April to 5 May 2020 (Study population B) Cabezón-Gutiérrez et al 2020 [107] 1st-19th June Oncology outpatients who attended the medical oncology consultation of the University Hospital of Torrejón Castro Dopico et al 2020 [108] 30th March -23rd August Blood Donors and pregnant women in Stockholm 13.7% (9.5-19.3%) estimated by ENS Learner Rudberg et al 2020 [109] 24th April -8th May HCWs at Danderyd Hospital 19.10% Lindahl et al 2020 [110] 20th April Employees of elderly care homes situated in Stockholm city and its suburbs 23% (20.4-25.7%) Roxhed et al 2020 [111] 20th April Households in Stockholm 4.4% (2.4%-6.3%) for IgG Lidström et al 2020 [112] 27 th May-25 TH June All healthcare staff including support staff, in the Region Uppsala Lundkvist et al 2020 [113] 17th Thompson et al 2020 [118] 17th March -19th May 2020 Blood donors in Scotland 3.17% Houlihan et al 2020 [119] 26th March -8th April HCWs at University College London Hospitals (UCLH) who work in accident and emergency (A&E), COVID ward, acute medical unit (AMU), intensive care (ICU) or haematology Pallett et al 2020 [120] 8th April -12th June HCWs in two hospitals in London 39.30% Waterfield et al 2020 [121] 16th April -3rd July Children of healthcare workers, aged between 2 and 15 years 6.90% Eyre et al 2020 [122] 23rd April -8th June Hospital staff at Oxford University Hospitals NHS Foundation Trust Shields et al 2020 [123] 24th -25th April HCWs at University of Birmingham and University Hospitals Birmingham NHS Foundation Trust 24.40% UK Clarke et al 2020 [124] 27th April -7th May Patients receiving in centre haemodialysis (ICHD) within two units affiliated with Imperial College Renal and Transplant Centre Wells et al 2020 [125] 27th April -2nd June Participants of the Twins UK Cohort Study 12.00% The Government of Jersey 2020 [126] 29th April -5th May Residents in Jersey over 16 years of age 3.1% (+/-1.3%) Poulikakos et al 2020 [127] 4th-6th May HCWs from renal and biochemistry department in a tertiary hospital in the northwest of England 6.00% Khalil et al 2020 [128] 15th -28th May HCWs at Portland Hospital for Women and Children Grant et al 2020 [129] 15th May -5th June HCWs at Whittington Health 31.64% Ladhani et al 2020 [130] 20th Fig 2B shows the seroprevalence of HCWs categorised by their risk of exposure to SARS--CoV-2 patients over time. All subgroups with a seroprevalence of >30% belonged to either medium or high risk. The majority (67/79) of the subgroups had a seroprevalence of less than 20% regardless of their risk. There was no significant difference in seroprevalence amongst HCWs when stratified by country (Fig 3) . There is a large amount of heterogeneity between the studies (I 2 value = 99.27%, p = 0.00). There was no reduction in heterogeneity when moderate risk of bias studies were removed. Similarly, when the seroprevalence amongst HCWs was stratified by their risk of exposure to SARS-CoV-2 patients there was no significant difference (S1 Fig). Community studies. In total 34 studies were set in the community, spanning 13 countries. The studies collected data between February 2020-August 2020. Ten of these studies collected samples from blood donors; five studies used residual serum samples from clinics, laboratories and hospital facilities; one study used tissues samples and the remaining studies were randomised population-based studies. The overall lowest seroprevalence was reported in Greece in March 2020 of 0.24% (0.03-0.45%) [67] . The same study reported an increase in seroprevalence in April of 0.42% (0.23-0.61%). The overall highest seroprevalence was reported in Lodi, Italy during the months of March and April at 23% [76] . The majority of studies reported an overall seroprevalence of less than 10% during the months of February-August 2020 (Fig 2C) . Age. Many of the community studies report the seroprevalence among different age groups. There is significant heterogeneity between the results. In general, lower seroprevalences were reported at the extremes of age. Several studies report a higher seroprevalence among the over 50 age group [40, 52, 74, 85, 86, 104] . In contrast some studies report a higher seroprevalence in the less than 30 years age group, these include studies from Switzerland, the Netherlands, Denmark, France, Luxembourg and the UK [45, 90, 91, 115, 131, 137] . Gender. In the majority of community studies there was no significant difference identified by gender. However, two studies reported a significantly higher number of female participants having antibodies against SARS-CoV-2 [45, 74] . Carrat et al investigated the seroprevalence in three administrative regions of France Ile-de-France (IDF), Grand Est (GE) and Nouvelle- 13.3% using Luminex assay on day 28 Ladhani et al 2020 [136] June-July Teachers and students in 131 schools across England 11.7% (10.5-13.3%) Ward et al 2020 [137] 20th June -13th July Residents in England over the age of 18 years 6% (5. Moderate risk Not enough information given about definition of a positive result, non-responder bias and discrepancies in the tables. Psichogiou et al 2020 [68] Low risk Tsitsilonis et al 2020 [69] Moderate risk Not enough information given about the sampling frame, selection process and nonresponse bias. Gudbjartsson et al 2020 [70] Low risk Plebani et al 2020 [71] Low risk Valenti et al 2020 [72] Low risk Pancrazzi et al 2020 [73] Moderate risk Not enough information given about the sampling frame, selection process and nonresponse bias. Vena et al 2020 [74] Moderate risk Not enough information given about the sampling frame, selection process and nonresponse bias. Norsa et al 2020 [ Moderate risk Not enough information given about the sampling frame, definition of a positive result, selection process and non-response bias. Castro Dopico et al 2020 [108] Moderate risk Not enough information given about the sampling frame, definition of a positive result, selection process and non-response bias. Rudberg et al 2020 [109] Low risk Lindahl et al 2020 [110] Low risk Roxhed et al 2020 [111] Moderate risk Not enough information given about the sampling frame, definition of a positive result, selection process and non-response bias. Lidstrom et al 2020 [112] Low risk Lundkvist et al 2020 [113] Low risk Emmenegger et al 2020 [114] Low risk Stringhini et al 2020 [115] Low risk Ulyte et al 2020 [116] Moderate risk Not enough information given about the sampling frame, definition of a positive result, selection process and non-response bias. Alkurt et al 2020 [117] Low risk Thompson et al 2020 [118] Moderate risk Not enough information given about the sampling frame, definition of a positive result, selection process and non-response bias. Houlihan et al 2020 [119] Low risk Pallett et al 2020 [120] Low risk Waterfield et al 2020 [121] Moderate risk Not enough information given about the sampling frame, definition of a positive result, selection process and non-response bias. Eyre et al 2020 [122] Moderate risk High non-response rate and not enough information given if the same test was used on all participants and definition of a positive result. Shields et al 2020 [123] Low risk UK Clarke et al 2020 [124] Low risk Wells et al 2020 [125] Moderate risk High non-response rate and not enough information given about the sampling frame and selection process. The Government of Jersey 2020 [126] Low risk Poulikakos et al 2020 [127] Moderate risk Not enough information given about the sampling frame, selection process and nonresponse bias. Khalil et al 2020 [128] Moderate risk Not enough information given about the sampling frame, selection process and nonresponse bias. Grant et al 2020 [129] Low risk Ladhani et al 2020 [130] Low risk Biobank 2020 [131] Low risk Public Health England 2020 [132] Moderate risk Not enough information given about the sampling frame, selection process and nonresponse bias. Blood donors. Many studies report the seroprevalence in blood donors as they are usually healthy individuals who represent the general population. There was a large variation in seroprevalence among blood donors between countries and over time. The lowest seroprevalence in blood donors was reported in Germany between March and June 2020 of 0.91% (0.58-1.24%) [53]. In contrast Percivalle et al reported the highest seroprevalence amongst Italian blood donors in April, living in the Lodi Red Zone of 23.3% [76] . The Lombardi Red Zone is an area of 10 municipalities that were put in total social and commercial lockdown from the 23 rd February 2020 [76] .The same study reports a seroprevalence of 1.67% in February 2020. In addition a study in the South East of Italy reports a seroprevalence on 0.99% in May 2020 [85] . Similar variations of estimates of seroprevalence were reported in blood donors in the UK. A study conducted in Scotland reported a seroprevalence of 3.17% between the months of March-May 2020 [118] . A seroprevalence of 8.5% (6.9-10%) was reported in blood donors across England in May [132] . Children/ Schools. Seven studies investigated the seroprevalence in school/university settings or among children only, across 5 different countries [49, 64, 69, 116, 121, 136] . Four of the studies examined the seroprevalence in schools [49, 64, 116, 136] . The lowest seroprevalence was reported in Germany; 0.6% among students in grade 8-11 and their teachers in 13 secondary schools in eastern Saxony between the months of May-June 2020 [64] . The highest seroprevalence of 11.7% was reported in students and teachers across schools in England between June-July 2020 (10.5-13.3%) [136] . Fontanet et al investigate the seroprevalence in a high school following an outbreak [44] . They report an overall seroprevalence of 25.86% among pupils, staff and parents of high school pupils [44] . Following the original outbreak Fontanet et al then investigated the seroprevalence among pupils and teachers in primary schools in the local area and reported an overall seroprevalence of 10.4% [49] . They noted that 41.4% of infected children had asymptomatic infection compared to 9.9% of seropositive adults [49] . One study examined the seroprevalence among university students and staff in Greece [69] . They reported an overall seroprevalence of 1%, with no significant difference by age, gender, school or position [69] . Outbreaks. Eight studies across four countries investigated the seroprevalence following an outbreak of SARS-CoV2 [24, 43, 44, 49, 58, 62, 130, 134] . Two of the studies were conducted in the UK and reported a high prevalence of antibodies against SARS-CoV-2 in residents and staff in care homes/nursing homes where there had been a recent SARS-CoV-2 outbreak [130, 134] . They report a high prevalence of antibodies against SARS-CoV-2. Ladhani et al estimated a seroprevalence of 77.9% (73.6-81.7%) and Nsn et al report a seroprevalence of 71.8% [130, 134] . Four studies report seroprevalences following outbreaks among blood donors or communities [24, 43, 58, 62] . They report much lower rates of seroprevalence compared to nursing home outbreaks. Grzelak et al investigated the seroprevalence of pauci-symptomatic individuals in Crepy-en-Valois France and blood donors in the surrounding region following an outbreak; they reported a seroprevalence of 3% in blood donors and 32% in the paucisymptomatic individuals [43] . Similarly, studies in Germany following community outbreaks report low rates of seroprevalence among residents. Streeck et al reported a prevalence of SARS-CoV-2 antibodies of 13.6% and Weis et al reported a seroprevalence of 8.4% [58, 62] . Fig 2D shows the seroprevalence of these outbreak studies over time. Pregnancy. Four studies examined the seroprevalence of SARS-CoV-2 in pregnant women [37, 50, 83, 97] . Two of these studies conducted in Italy between April-June 2020 reported a prevalence of SARS-CoV-2 antibodies of 10.1% and 14.3% in pregnant women in their first trimester screening or at delivery [83, 97] Assays. In total 47 different commercial assays and 22 in-house assays were used. The majority of studies used more than one assay. Of the commercial assays 11 were enzyme-linked immunosorbent assay (ELISA), seven were chemiluminescent microparticle immunoassays, two were based on flow cytometry and 27 were point of care tests (POC). The most used commercial assay was the SARS-CoV-2 (IgA/IgG) ELISA EUROIMMUN Medizinische Labordiagnostik, Lübeck, Germany (Table in S2 Table) . Our systematic review demonstrates a large variation in the seroprevalence of SARS-CoV-2 antibodies throughout Europe in the first half of 2020. HCWs in the UK had a much higher seroprevalence compared to HCWs in the rest of Europe during the months of March and August 2020. There are nine studies which took place in UK and six of them reported a seroprevalence of more 20% among HCWs [119, 120, 123, 128, 129, 133] . In contrast, Italy reports a low seroprevalence among HCWs. Of 10 studies among HCWs in Italy, nine reported a seroprevalence of SARS-CoV-2 antibodies of less than 10% [71, 77-82, 87, 88] . Both countries included studies from a mixture of high, medium and low risk HCWs and during this time both countries had high numbers of SARS-CoV-2 infections. In health care settings, the risk of HCWs of SARS CoV-2 exposure was determined by the COVID-19 caseload coming though the facility and the application of infection control measures. Infection control practices in relation to personal protective equipment (PPE) may in part explain some of the differences. Between European countries there are differences in the recommended PPE. The UK government guidelines on PPE include the use of eye/face protection, filtering facepiece class 3 (FFP3) respirator, disposable fluid-repellent coverall, and disposable gloves for aerosol-generating procedures and higher-risk acute care areas. For all inpatient ward settings eye/face protection, fluid-resistant (type IIR) surgical mask (FRSM), disposable plastic apron and disposable gloves are recommended [138] . In comparison, the National Institute of Health in Italy recommended that all HCWs wear a full-length gown with long sleeves, hairnet, goggles, gloves and surgical mask in the case of low-risk patients, and hairnet, googles or face-shield, FFP3 mask, water-resistant gown with long sleeves, and two pairs of gloves (second one covering the wrist of gown sleeves) for high risk patients and SARS-CoV-2 positive patients [77] . The main difference in the PPE provided in both countries was that Italy recommended that for all HCWs a full-length gown should be worn, a hairnet and an FFP3 mask when caring for all high-risk patients and all SARS-CoV-2 positive patients. As evidence now supports aerosol spread of SARS-CoV-2, reviews have been conducted investigating the protectiveness of surgical face masks and FFP3 masks. One such study concluded that surgical face masks provide no protection against aerosol particles, in comparison FFP3 masks provided adequate protection [139] . Although the availability and differences in PPE across European countries may partly explain the difference in seroprevalence seen in HCWs, there are other factors that require consideration. For example, differences in public health strategies and the time of their implementation such as the public wearing face masks, closure of educational settings and other public facilities. Furthermore, differences in adherence to infection control measures such as hand hygiene and social distancing could also explain the difference in seroprevalence seen among HCWs across Europe. Our systematic review found that in the majority of studies in Europe there was no difference in seroprevalence between female and male participants. Our findings are in keeping with a meta-analysis which showed there was no difference in the proportion of males and females with confirmed COVID-19 [140] . Throughout the current pandemic there has been debate on the role of children in the transmission of SARS-CoV-2 and the need for school closure to slow the pandemic. In this review three studies were conducted in schools not involved in an outbreak of SARS-CoV-2. A study in Germany reported the lowest seroprevalence among students and teachers in a school of 0.6% considered by the authors to be in keeping with local surveillance data of the surrounding community [64] . Ulyte et al reported that seroprevalence is inversely related to age in their school study [116] . They conclude this could be due to the lack of social distancing among young children and differences in immune response [116] . In contrast Ladhani et al reported no significant difference between the seroprevalence in students compared to staff [136] . However all studies concluded that there was no major transmission in schools and that the majority of children were asymptomatic or had mild symptoms [64, 116, 136] . However, since these studies have been conducted there has been the introduction of the SARS-CoV-2 variants; B 1.1.7 and B 1.617.2. An increase in these variants have been seen among children and young adolescents with outbreaks occurring in schools and child-care facilities [141, 142] . As new variants emerge it would be reasonable for more school-based studies investigating the seroprevalence among staff and students to be conducted to fully understand transmission dynamics and immune response over time. Viewed within the context of local community data this will help to inform public health strategies to both protect children and to minimise transmission in the wider community. In studies conducted during local outbreaks, there was a noticeable difference between those conducted in care/nursing homes compared to community and school settings. Those that took place in care/ nursing homes reported a seroprevalence as high as 77.9%, whereas those in a community setting reported a seroprevalence ranging from 3% -42.4% and those in a school reported a seroprevalence between 10.4% and 25.86% [24, 43, 44, 49, 58, 62, 130] This large discrepancy could be attributable to the close proximity of care/nursing home residents, shared living spaces and the intimate care and handling of residents by staff. This systematic review and meta-analysis had several limitations. Firstly, of the 115 studies included in this review, not all of them could be included in sub-analysis as complete data sets could not be retrieved from every study and data quality was heterogeneous. As this review only included studies performed in Europe, the results of this review can only be applied to European countries. By only including papers written in English we may have overlooked important seroprevalence studies conducted in Europe but published in another language. In addition, most studies were performed either in the UK, Italy, Spain or Germany. There was a large gap in studies being performed in Eastern European countries. Those studies performed in the UK predominately took place in the South of England. Therefore, our review maybe bias towards countries and regions where there is more funding and resources available to conduct seroprevalence studies. In this review the studies used a variety of different assays, with different sensitivities and specificities which could lead to an under or overestimation of the true prevalence reported. Furthermore, many of the studies were pre-print articles that had not undergone peer-review; however, study quality was assessed and subgroup analysis based on risk of bias was performed. This systematic review and metanalysis highlights substantial heterogeneity between countries, within countries, among professions, and among settings. This heterogeneity, in addition to indicating the general trajectory of the pandemic in different regions, might have been driven by a variety of other factors including governmental policies and restrictions, local guidelines and restrictions, availability of PPE, the time period when the study was conducted and serological test performance. Nevertheless, seroprevalence studies yield large amounts of useful, locally relevant information and should be regularly repeated as the pandemic evolves and local guidelines and restrictions change. As testing standardises and new studies are reported they will also help identify different national experiences across Europe and provide a means to distil best pandemic control practices for the future. As mass vaccinations have been launched in many countries seroprevalence studies will be able to provide valuable information on the immune response over time following vaccination and the need for booster vaccinations, help understand if herd immunity has been achieved and identify populations at risk of transmission and therefore need for vaccination. Finally, as new variants of SARS-CoV-2 now emerge, and many countries prepare for future waves it is vital that regular seroprevalence studies are conducted to aid control by informing public health measures. Supporting information S1 Table. Breakdown of quality of assessment results. (XLSX) S2 Table. Commercial assays and their specificity and sensitivity according to the manufacturer. In some cases, the manufacture's specificity and sensitivity were unable to be found, so evaluation study data was used instead. (PDF) World Health Organization. WHO Director-General's opening remarks at the media briefing on COVID-19-11 SARS-CoV2 in Different Body Fluids, Risks of Transmission, and Preventing COVID-19: A Comprehensive Evidence-Based Review Consideration of the Aerosol Transmission for COVID-19 and Public Health Ten scientific reasons in support of airborne transmission of SARS-CoV-2 Clinical Characteristics of Coronavirus Disease 2019 in China Covid-19: four fifths of cases are asymptomatic, China figures indicate Observation and analysis of 26 cases of asymptomatic SARS-COV2 infection European Centre for Disease Prevention and control. Population-wide testing of SARS-CoV-2: country experiences and potential approaches in the EU/EEA and the United Kingdom European Commission request Definition World Health Organization. COVID-19 Strategy Update Covid-19: Mass population testing is rolled out in Liverpool Are we underestimating seroprevalence of SARS-CoV-2? Testing for SARS-CoV-2 antibodies Seroprevalence of Ebola virus infection in Bombali District Resurgence risk for measles, mumps and rubella in France The PRISMA 2020 statement: an updated guideline for reporting systematic reviews World Health Organization (WHO) World Health Organisation. World Health Organization Assessing risk of bias in prevalence studies: modification of an existing tool and evidence of interrater agreement A Meta-Analysis of the Metabolic Syndrome Prevalence in the Global HIV-Infected Population How to Conduct a Meta-Analysis of Proportions in R: A Comprehensive Tutorial Seroprevalence and correlates of SARS-CoV-2 neutralizing antibodies: Results from a population-based study in Bonn Seroprevalence of SARS-CoV-2 antibodies in an entirely PCR-sampled and quarantined community after a COVID-19 outbreak -the CoNAN study Seroprevalence of SARS CoV-2 antibodies in healthcare workers and administration employees: a prospective surveillance study at a 1,400-bed university hospital in Germany Anti-SARS-CoV-2 IgG antibodies in adolescent students and their teachers in Saxony, Germany (SchoolCoviDD19): very low seropraevalence and transmission rates. medRxiv Seroprevalence of COVID-19 antibodies in the cleaning and oncological staff of a municipal clinic Testing the backbone of the healthcare system: a prospective serological-epidemiological cohort study of healthcare workers in rural Germany Repeated leftover serosurvey of SARS-CoV-2 IgG antibodies Antibodies against SARS-CoV-2 among health care workers in a country with low burden of COVID-19. medRxiv Seroprevalence of antibodies against SARS-CoV-2 among the personnel and students of the national and kapodistrian university of athens, greece: A preliminary report Humoral Immune Response to SARS-CoV-2 in Iceland SARS-CoV-2 serosurvey in health care workers of the Veneto Region SARS-CoV-2 seroprevalence trends in healthy blood donors during the COVID-19 Milan outbreak Comparison of serologic and molecular SARS-CoV 2 results in a large cohort in Southern Tuscany demonstrates a role for serologic testing to increase diagnostic sensitivity Prevalence of Antibodies to SARS-CoV-2 in Italian Adults and Associated Risk Factors Asymptomatic SARS-CoV-2 infection in patients with inflammatory bowel disease under biologic treatment Prevalence of SARS-CoV-2 specific neutralising antibodies in blood donors from the Prevalence of Sars-Cov-2 Infection in Health Workers (HWs) and Diagnostic Test Performance: The Experience of a Teaching Hospital in Central Italy COVID-19 among healthcare workers in a specialist infectious diseases setting in Naples, Southern Italy: results of a cross-sectional surveillance study SARS-CoV-2 specific serological pattern in healthcare workers of an Italian COVID-19 forefront hospital Low seroprevalence of SARS-CoV-2 infection among healthcare workers of the largest children hospital in Milan during the pandemic wave Detection of asymptomatic SARS-CoV-2 infections among healthcare workers: results from a large-scale screening program based on rapid serological testing COVID-19 experience: first Italian survey on healthcare staff members from a Mother-Child Research Hospital using combined molecular and rapid immunoassays test The "scar" of a pandemic: Cumulative incidence of COVID-19 during the first trimester of pregnancy IgG serology in health care and administrative staff populations from 7 hospital representative of different exposures to SARS-CoV-2 in Lombardy Results from a survey in healthy blood donors in South Eastern Italy indicate that we are far away from herd immunity to SARS-CoV-2 Seroprevalence of SARS-CoV-2 significantly varies with age: Preliminary results from a mass population screening SARS-CoV-2 infection in healthcare workers: cross-sectional analysis of an Otolaryngology Unit 2 Severe Acute Respiratory Syndrome Coronavirus 2 Serology in Asymptomatic Healthcare Professionals: Preliminary Experience of a Tertiary Italian Academic Center Homologous and heterologous antibodies to coronavirus 229E, NL63, OC43, HKU1, SARS, MERS and SARS-CoV-2 antigens in an age stratified cross-sectional serosurvey in a large tertiary hospital in The Netherlands. medRxiv [Internet] Herd immunity is not a realistic exit strategy during a COVID-19 outbreak Prevalence of SARS-CoV-2 infection in the Luxembourgish population: the CON-VINCE study. medRxiv Seroprevalence of anti-SARS-CoV-2 antibodies in COVID-19 patients and healthy volunteers Seroprevalence of SARS-CoV-2 Among Pediatric Healthcare Workers in Spain. Front Pediatr Seroprevalence of antibodies against SARS-CoV-2 among health care workers in a large Spanish reference hospital Caveats in interpreting SARS-CoV-2 IgM+ /IgG-antibody profile in asymptomatic health care workers SARS-CoV-2 SEROPREVALENCE AMONG ALL WORKERS IN A TEACHING HOSPITAL IN SPAIN: UNMASK-ING THE RISK. medRxiv Seroprevalence and presentation of SARS-CoV-2 in pregnancy Impact of SARS-CoV-2 pandemic among health care workers in a secondary teaching hospital in Spain Search for asymptomatic carriers of SARS-CoV-2 in healthcare workers during the pandemic: a Spanish experience Prevalence of SARS-CoV-2 infection in general practitioners and nurses in primary care and nursing homes in the Healthcare Area of Leó n and associated factors Community seroprevalence of COVID-19 in probable and possible cases at primary health care centres in Spain SARS-CoV-2 infections and antibody responses among health care workers in a Spanish hospital after a month of follow-up. medRxiv SARS-CoV-2 antibodies in adults in Madrid, Spain. Clin Infect Dis Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study IgG seroprevalence against SARS-CoV-2 in a cohort of 449 non-hospitalized, high-risk exposure individuals. Res Sq Seroprevalence of SARS-CoV-2 IgG Specific Antibodies among Healthcare Workers in the Northern Metropolitan Area of Barcelona, Spain, after the first pandemic wave Seroprevalence of SARS-CoV-2-specific antibodies in cancer outpatients in Madrid (Spain): A single center, prospective, cohort study and a review of available data. Cancer Treat Rev Antibody phenotypes and probabilistic seroprevalence estimates during the emergence of SARS-CoV-2 in Sweden SARS-CoV-2 exposure, symptoms and seroprevalence in health care workers High seroprevalence of SARS-CoV-2 in elderly care employees in Sweden A translational multiplex serology approach to profile the prevalence of anti-SARS-CoV-2 antibodies in home-sampled blood Work at inpatient care units is associated with an increased risk of SARS-CoV-2 infection; a cross-sectional study of 8679 healthcare workers in Sweden Pronounced difference in Covid-19 antibody prevalence indicates cluster transmission in Early peak and rapid decline of SARS-CoV-2 seroprevalence in a Swiss metropolitan region. medRxiv Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study Variation in SARS-CoV-2 seroprevalence in school-children across districts, schools and classes [Internet]. medRxiv Seroprevalence of Coronavirus Disease 2019 (COVID-19) Among Health Care Workers from Three Pandemic Hospitals of Turkey. medRxiv Detection of neutralising antibodies to SARS coronavirus 2 to determine population exposure in Scottish blood donors between SARS-CoV-2 virus and antibodies in frontline Health Care Workers in an acute hospital in London: preliminary results from a longitudinal study Point-of-care serological assays for delayed SARS-CoV-2 case identification among health-care workers in the UK: a prospective multicentre cohort study Seroprevalence of SARS-CoV-2 antibodies in children: a prospective multicentre cohort study Differential occupational risks to healthcare workers from SARS-CoV-2: A prospective observational study. medRxiv SARS-CoV-2 seroprevalence and asymptomatic viral carriage in healthcare workers: a cross-sectional study High Prevalence of Asymptomatic COVID-19 Infection in Hemodialysis Patients Detected Using Serologic Screening Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England SARS-CoV-2: Prevalence of antibodies in Jersey SARS-CoV-2 antibody screening in healthcare workers in a tertiary centre in North West England SARS-CoV-2-specific antibody detection in healthcare workers in a UK maternity Hospital: Correlation with SARS-CoV-2 RT-PCR results Seroprevalence of SARS-CoV-2 antibodies in healthcare workers at a London NHS Trust High prevalence of SARS-CoV-2 antibodies in care homes affected by COVID-19; a prospective cohort study in England UK Biobank SARS-CoV2 Serology Study Self assessment overestimates historical COVID-19 disease relative to sensitive serological assays: cross sectional study in UK key workers High rates of SARS-CoV-2 seropositivity in nursing home residents SARS-CoV-2 antigen and antibody prevalence among UK staff working with cancer patients during the COVID-19 pandemic Prospective active national surveillance of preschools and primary schools for SARS-CoV-2 infection and transmission in England Antibody prevalence for SARS-CoV-2 in England following first peak of the pandemic: REACT2 study in 100,000 adults. medRxiv Availability of Personal Protective Equipment in NHS Hospitals During COVID-19: A National Survey. Ann Work Expo Heal COVID-19: smoke testing of surgical mask and respirators Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission. Nat Commun Covid-19 and the delta variant-we need an urgent focus on mitigations in schools-The BMJ SARS-CoV-2 variant B.1.1.7 susceptibility and infectiousness of children and adults deduced from investigations of childcare centre outbreaks Each study underwent a risk of bias assessment using the modified Hoy et al risk of bias tool [18] . Twenty nine of the 115 studies were deemed to be at moderate risk of bias [31, 34, 42, 44, 47, 54, 56, 57, 67, 69, 73, 74, 88, 95, 97, 100, 107, 108, 111, 116, 118, 121, 122, 125, 127, 128,